You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePropranolol
Accession NumberDB00571  (APRD00194)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA widely used non-cardioselective beta-adrenergic antagonist. Propranolol is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety. [PubChem]
Structure
Thumb
Synonyms
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
beta-Propranolol
Propanalol
Propanolol
Propranolol
Propranololo
Propranololum
β-Propranolol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Detensol Tab 10mgtablet10 mgoralDesbergers LtÉe, Division Of Technilab Inc.1980-12-311999-09-17Canada
Detensol Tab 120mgtablet120 mgoralDesbergers LtÉe, Division Of Technilab Inc.1981-12-311999-09-17Canada
Detensol Tab 40mgtablet40 mgoralDesbergers LtÉe, Division Of Technilab Inc.1980-12-311999-09-17Canada
Detensol Tab 80mgtablet80 mgoralDesbergers LtÉe, Division Of Technilab Inc.1980-12-311999-09-17Canada
Dom-propranolol Tabletstablet40 mgoralDominion Pharmacal1996-12-31Not applicableCanada
Dom-propranolol Tabletstablet10 mgoralDominion Pharmacal1996-12-31Not applicableCanada
Dom-propranolol Tablets - 80mgtablet80 mgoralDominion Pharmacal1996-12-31Not applicableCanada
Hemangeolsolution4.28 mg/mLoralPierre Fabre Pharmaceuticals, Inc.2014-04-14Not applicableUs
Inderal 20 Tab 20mgtablet20 mgoralAyerst Laboratories1984-12-311999-04-12Canada
Inderal 80 Tabtablet80 mgoralAyerst Laboratories1974-12-311996-09-10Canada
Inderal Injectable Liq 1mg/mlliquid1 mgintravenousWyeth Ayerst Canada Inc.1995-12-312003-04-17Canada
Inderal LAcapsule, extended release80 mg/1oralAkrimax Pharmaceuticals, LLC1983-04-19Not applicableUs
Inderal LAcapsule, extended release120 mg/1oralAkrimax Pharmaceuticals, LLC1983-04-19Not applicableUs
Inderal LAcapsule, extended release160 mg/1oralAkrimax Pharmaceuticals, LLC1983-04-19Not applicableUs
Inderal LAcapsule, extended release60 mg/1oralAkrimax Pharmaceuticals, LLC1983-04-19Not applicableUs
Inderal LA Cap 160mgcapsule (sustained-release)160 mgoralAyerst Laboratories1980-12-311996-09-10Canada
Inderal LA Cap 80mgcapsule (sustained-release)80 mgoralAyerst Laboratories1982-12-311996-09-10Canada
Inderal Tab 120mgtablet120 mgoralAyerst Laboratories1979-12-311997-08-15Canada
Inderal XLcapsule, extended release80 mg/1oralMist Pharmaceuticals, Llc2014-02-01Not applicableUs
Inderal XLcapsule, extended release120 mg/1oralMist Pharmaceuticals, Llc2014-02-01Not applicableUs
Inderal-10 Tab 10mgtablet10 mgoralWyeth Ayerst Canada Inc.1994-12-312004-07-27Canada
Inderal-120 Tab 120mgtablet120 mgoralWyeth Ayerst Canada Inc.1996-10-252001-02-02Canada
Inderal-20 Tab 20mgtablet20 mgoralWyeth Ayerst Canada Inc.1994-12-312002-05-17Canada
Inderal-40 Tab 40mgtablet40 mgoralWyeth Ayerst Canada Inc.1993-12-312002-05-17Canada
Inderal-80 Tab 80mgtablet80 mgoralWyeth Ayerst Canada Inc.1996-10-252001-05-07Canada
Inderal-LAcapsule (sustained-release)60 mgoralPfizer Canada Inc1995-12-31Not applicableCanada
Inderal-LAcapsule (sustained-release)80 mgoralPfizer Canada Inc1994-12-31Not applicableCanada
Inderal-LAcapsule (sustained-release)120 mgoralPfizer Canada Inc1994-12-31Not applicableCanada
Inderal-LAcapsule (sustained-release)160 mgoralPfizer Canada Inc1994-12-31Not applicableCanada
Innopran XLcapsule, extended release80 mg/1oralAkrimax Pharmaceuticals, LLC2013-06-01Not applicableUs
Innopran XLcapsule, extended release120 mg/1oralAkrimax Pharmaceuticals, LLC2013-06-01Not applicableUs
Novo-pranol Tab 120mgtablet120 mgoralNovopharm Limited1982-12-312005-08-10Canada
Nu-propranolol Tab 10mgtablet10 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Nu-propranolol Tab 120mgtablet120 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Nu-propranolol Tab 20mgtablet20 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Nu-propranolol Tab 40mgtablet40 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Nu-propranolol Tab 80mgtablet80 mgoralNu Pharm Inc1993-12-312012-09-04Canada
PMS-propranolol Tablets 10mgtablet10 mgoralPharmascience Inc1983-12-31Not applicableCanada
PMS-propranolol Tablets 120mgtablet120 mgoralPharmascience Inc1983-12-31Not applicableCanada
PMS-propranolol Tablets 40mgtablet40 mgoralPharmascience Inc1983-12-31Not applicableCanada
PMS-propranolol Tablets 80mgtablet80 mgoralPharmascience Inc1983-12-31Not applicableCanada
Propranolol Hydrochloride ERcapsule, extended release60 mg/1oralRouses Point Pharm1983-04-19Not applicableUs
Propranolol Hydrochloride ERcapsule, extended release120 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Propranolol Hydrochloride ERcapsule, extended release80 mg/1oralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs
Propranolol Hydrochloride ERcapsule, extended release120 mg/1oralUnit Dose Services1983-04-19Not applicableUs
Propranolol Hydrochloride ERcapsule, extended release80 mg/1oralRouses Point Pharm1983-04-19Not applicableUs
Propranolol Hydrochloride ERcapsule, extended release160 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Propranolol Hydrochloride ERcapsule, extended release120 mg/1oralRouses Point Pharm1983-04-19Not applicableUs
Propranolol Hydrochloride ERcapsule, extended release60 mg/1oralAmerican Health Packaging2013-07-05Not applicableUs
Propranolol Hydrochloride ERcapsule, extended release160 mg/1oralRouses Point Pharm1983-04-19Not applicableUs
Propranolol Hydrochloride ERcapsule, extended release80 mg/1oralAmerican Health Packaging2013-07-05Not applicableUs
Propranolol Hydrochloride Injection USPsolution1 mgintravenousSandoz Canada Incorporated1996-10-04Not applicableCanada
Propranolol Hydrochloride Tablet 40mgtablet40 mgoralD.C. Labs Limited1982-12-312003-07-11Canada
Propranolol Tab 10mgtablet10 mgoralPro Doc Limitee1980-12-312010-07-13Canada
Propranolol Tab 40mgtablet40 mgoralPro Doc Limitee1980-12-312010-07-13Canada
Propranolol Tab 80mgtablet80 mgoralPro Doc Limitee1980-12-312010-07-13Canada
Propranolol-120 Tab 120mgtablet120 mgoralPro Doc Limitee1987-12-312010-07-13Canada
Propranolol-20 Tab 20mgtablet20 mgoralPro Doc Limitee1987-12-312010-07-13Canada
Teva-propranololtablet10 mgoralTeva Canada Limited1981-12-31Not applicableCanada
Teva-propranololtablet20 mgoralTeva Canada Limited1987-12-31Not applicableCanada
Teva-propranololtablet40 mgoralTeva Canada Limited1981-12-31Not applicableCanada
Teva-propranololtablet80 mgoralTeva Canada Limited1981-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Propranolol Tab 10mgtablet10 mgoralApotex Inc1980-12-31Not applicableCanada
Apo Propranolol Tab 120mgtablet120 mgoralApotex Inc1981-12-31Not applicableCanada
Apo Propranolol Tab 40mgtablet40 mgoralApotex Inc1980-12-31Not applicableCanada
Apo Propranolol Tab 80mgtablet80 mgoralApotex Inc1980-12-31Not applicableCanada
Apo-propranolol Tab 20mgtablet20 mgoralApotex Inc1986-12-31Not applicableCanada
Propranololinjection1 mg/mLintravenousGeneral Injectables & Vaccines, Inc2011-02-22Not applicableUs
Propranololinjection, solution1 mg/mLintravenousAPP Pharmaceuticals, LLC2001-09-07Not applicableUs
Propranololtablet10 mg/1oralSTAT Rx USA LLC1986-01-01Not applicableUs
Propranololinjection1 mg/mLintravenousPhysicians Total Care, Inc.2006-12-11Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralWatson Laboratories, Inc.1986-05-13Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralNorthstar Rx LLC2009-12-14Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralAidarex Pharmaceuticals LLC2008-10-13Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2011-08-04Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralUnit Dose Services2008-10-13Not applicableUs
Propranolol Hydrochloridecapsule, extended release60 mg/1oralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Propranolol Hydrochloridetablet60 mg/1oralPhysicians Total Care, Inc.2006-03-30Not applicableUs
Propranolol Hydrochloridecapsule, extended release80 mg/1oralGolden State Medical Supply, Inc.2014-07-15Not applicableUs
Propranolol Hydrochloridecapsule, extended release60 mg/1oralCadila Healthcare Limited2014-04-15Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralAvera Mc Kennan Hospital2015-04-21Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralA S Medication Solutions2010-06-21Not applicableUs
Propranolol Hydrochloridetablet60 mg/1oralMylan Pharmaceuticals Inc.1985-11-19Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1985-11-19Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralHeritage Pharmaceuticals Inc.2008-10-13Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralAphena Pharma Solutions Tennessee, Llc2010-06-21Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralA S Medication Solutions Llc2010-06-21Not applicableUs
Propranolol Hydrochloridesolution20 mg/5mLoralRoxane Laboratories, Inc1987-05-15Not applicableUs
Propranolol Hydrochloridecapsule, extended release160 mg/1oralBreckenridge Pharmaceutical, Inc.2013-03-11Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralPhysicians Total Care, Inc.1993-07-27Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralPd Rx Pharmaceuticals, Inc.1986-05-13Not applicableUs
Propranolol Hydrochloridecapsule, extended release60 mg/1oralbryant ranch prepack2007-08-10Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralDispensing Solutions, Inc.2008-10-13Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-03-23Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralMylan Pharmaceuticals Inc.1985-11-19Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Propranolol Hydrochlorideinjection, solution1 mg/mLintravenousCardinal Health2003-02-26Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralDIRECT RX2014-01-01Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralCarilion Materials Management1986-05-13Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralPd Rx Pharmaceuticals, Inc.2010-06-21Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralQualitest Pharmaceuticals2010-06-21Not applicableUs
Propranolol Hydrochloridetablet80 mg/1oralNorthstar Rx LLC2009-12-14Not applicableUs
Propranolol Hydrochloridecapsule, extended release120 mg/1oralNortec Development Associates, Inc2015-05-01Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2013-03-20Not applicableUs
Propranolol Hydrochloridetablet50 mg/1oralREMEDYREPACK INC.2011-04-28Not applicableUs
Propranolol Hydrochloridetablet60 mg/1oralPliva Inc.1990-09-30Not applicableUs
Propranolol Hydrochloridecapsule, extended release80 mg/1oralActavis Elizabeth LLC2007-08-10Not applicableUs
Propranolol Hydrochloridecapsule, extended release60 mg/1oralPhysicians Total Care, Inc.2007-03-30Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralClinical Solutions Wholesale, Llc1990-09-30Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralbryant ranch prepack2008-10-13Not applicableUs
Propranolol Hydrochloridecapsule, extended release160 mg/1oralZydus Pharmaceuticals (USA) Inc.2014-04-15Not applicableUs
Propranolol Hydrochloridecapsule, extended release80 mg/1oralAvera Mc Kennan Hospital2015-05-15Not applicableUs
Propranolol Hydrochloridecapsule, extended release160 mg/1oralMylan Pharmaceuticals Inc.2007-02-15Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralAvera Mc Kennan Hospital2015-04-08Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2014-08-13Not applicableUs
Propranolol Hydrochloridetablet80 mg/1oralWatson Laboratories, Inc.1986-05-13Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralNorthstar Rx LLC2009-12-14Not applicableUs
Propranolol Hydrochloridetablet60 mg/1oralRebel Distributors Corp.2008-10-13Not applicableUs
Propranolol Hydrochloridetablet80 mg/1oralREMEDYREPACK INC.2011-10-13Not applicableUs
Propranolol Hydrochloridecapsule, extended release60 mg/1oralUnit Dose Services2007-08-10Not applicableUs
Propranolol Hydrochloridecapsule, extended release80 mg/1oralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Propranolol Hydrochloridecapsule, extended release80 mg/1oralPhysicians Total Care, Inc.2007-02-05Not applicableUs
Propranolol Hydrochloridecapsule, extended release120 mg/1oralGolden State Medical Supply, Inc.2014-07-15Not applicableUs
Propranolol Hydrochloridecapsule, extended release80 mg/1oralCadila Healthcare Limited2014-04-15Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralbryant ranch prepack2008-10-13Not applicableUs
Propranolol Hydrochloridecapsule, extended release60 mg/1oralZydus Pharmaceuticals (USA) Inc.2014-04-15Not applicableUs
Propranolol Hydrochloridecapsule, extended release60 mg/1oralMylan Pharmaceuticals Inc.2007-02-15Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1985-11-19Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralHeritage Pharmaceuticals Inc.2008-10-13Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2010-11-08Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralPliva Inc.1990-09-30Not applicableUs
Propranolol Hydrochloridesolution40 mg/5mLoralRoxane Laboratories, Inc1987-05-15Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2012-09-24Not applicableUs
Propranolol Hydrochloridetablet80 mg/1oralPhysicians Total Care, Inc.1995-08-18Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralPd Rx Pharmaceuticals, Inc.2008-10-13Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralRebel Distributors Corp1986-01-01Not applicableUs
Propranolol Hydrochloridecapsule, extended release160 mg/1oralNortec Development Associates, Inc2015-05-01Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralA S Medication Solutions Llc2010-06-21Not applicableUs
Propranolol Hydrochloridecapsule, extended release60 mg/1oralBreckenridge Pharmaceutical, Inc.2013-03-11Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralMylan Pharmaceuticals Inc.1985-11-19Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralCardinal Health2011-09-20Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralProficient Rx LP1990-09-30Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralCarilion Materials Management2010-06-21Not applicableUs
Propranolol Hydrochloridetablet60 mg/1oralQualitest Pharmaceuticals2010-06-21Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralWatson Laboratories, Inc.1986-05-13Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralAidarex Pharmaceuticals LLC2008-10-13Not applicableUs
Propranolol Hydrochloridecapsule, extended release60 mg/1oralREMEDYREPACK INC.2011-06-03Not applicableUs
Propranolol Hydrochloridetablet80 mg/1oralPliva Inc.1990-09-30Not applicableUs
Propranolol Hydrochloridecapsule, extended release120 mg/1oralActavis Elizabeth LLC2007-08-10Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Propranolol Hydrochloridecapsule, extended release120 mg/1oralPhysicians Total Care, Inc.1994-03-14Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralClinical Solutions Wholesale2010-06-21Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralTYA Pharmaceuticals2008-10-13Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralPreferred Pharmaceuticals, Inc.2012-07-26Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralA S Medication Solutions2010-06-21Not applicableUs
Propranolol Hydrochloridecapsule, extended release160 mg/1oralGolden State Medical Supply, Inc.2014-07-15Not applicableUs
Propranolol Hydrochloridecapsule, extended release120 mg/1oralCadila Healthcare Limited2014-04-15Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralAvera Mc Kennan Hospital2015-11-02Not applicableUs
Propranolol Hydrochloridecapsule, extended release80 mg/1oralA S Medication Solutions2013-03-11Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralQualitest Pharmaceuticals2010-06-21Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralNorthstar Rx LLC2009-12-14Not applicableUs
Propranolol Hydrochloridecapsule, extended release60 mg/1oralNortec Development Associates, Inc2015-05-01Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2011-05-24Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralUDL Laboratories, Inc.1998-09-01Not applicableUs
Propranolol Hydrochloridecapsule, extended release120 mg/1oralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralCardinal Health2008-10-13Not applicableUs
Propranolol Hydrochloridecapsule, extended release160 mg/1oralPhysicians Total Care, Inc.2007-05-02Not applicableUs
Propranolol Hydrochloridecapsule, extended release160 mg/1oralLake Erie Medical DBA Quality Care Products LLC2013-03-11Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralbryant ranch prepack1986-05-13Not applicableUs
Propranolol Hydrochloridecapsule, extended release80 mg/1oralZydus Pharmaceuticals (USA) Inc.2014-04-15Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC1990-09-30Not applicableUs
Propranolol Hydrochloridecapsule, extended release80 mg/1oralMylan Pharmaceuticals Inc.2007-02-15Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1990-09-30Not applicableUs
Propranolol Hydrochloridetablet60 mg/1oralHeritage Pharmaceuticals Inc.2008-10-13Not applicableUs
Propranolol Hydrochloridetablet80 mg/1oralREMEDYREPACK INC.2011-04-19Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralPliva Inc.1990-09-30Not applicableUs
Propranolol Hydrochlorideinjection1 mg/mLintravenousWest ward Pharmaceutical Corp2008-01-31Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralREMEDYREPACK INC.2014-05-08Not applicableUs
Propranolol Hydrochloridetablet80 mg/1oralQualitest Pharmaceuticals2010-06-21Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralRebel Distributors Corp1986-01-01Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralPd Rx Pharmaceuticals, Inc.1986-05-13Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralA S Medication Solutions Llc2008-10-13Not applicableUs
Propranolol Hydrochloridecapsule, extended release80 mg/1oralBreckenridge Pharmaceutical, Inc.2013-03-11Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralMylan Pharmaceuticals Inc.1985-11-19Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralPhysicians Total Care, Inc.2003-02-27Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralCardinal Health2011-09-20Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralCarilion Materials Management2008-10-13Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralWatson Laboratories, Inc.1986-05-13Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralAidarex Pharmaceuticals LLC2008-10-13Not applicableUs
Propranolol Hydrochloridecapsule, extended release80 mg/1oralREMEDYREPACK INC.2011-07-28Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralUnit Dose Services2008-10-13Not applicableUs
Propranolol Hydrochloridecapsule, extended release160 mg/1oralActavis Elizabeth LLC2007-08-10Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Propranolol Hydrochloridecapsule, extended release60 mg/1oralGolden State Medical Supply, Inc.2014-07-15Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralTYA Pharmaceuticals2008-10-13Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralPreferred Pharmaceuticals, Inc.2012-07-26Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralA S Medication Solutions2010-06-21Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralCardinal Health2011-09-20Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2015-06-18Not applicableUs
Propranolol Hydrochloridecapsule, extended release160 mg/1oralCadila Healthcare Limited2014-04-15Not applicableUs
Propranolol Hydrochloridesolution20 mg/5mLoralCarilion Materials Management1987-05-15Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralQualitest Pharmaceuticals2010-06-21Not applicableUs
Propranolol Hydrochloridetablet60 mg/1oralNorthstar Rx LLC2009-12-14Not applicableUs
Propranolol Hydrochloridecapsule, extended release80 mg/1oralNortec Development Associates, Inc2015-05-01Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-23Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralUDL Laboratories, Inc.1998-09-01Not applicableUs
Propranolol Hydrochloridecapsule, extended release160 mg/1oralUpsher Smith Laboratories, Inc.2011-05-02Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralPliva Inc.1990-09-30Not applicableUs
Propranolol Hydrochloridecapsule, extended release60 mg/1oralActavis Elizabeth LLC2007-08-10Not applicableUs
Propranolol Hydrochlorideinjection1 mg/mLintravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Propranolol Hydrochloridecapsule, extended release80 mg/1oralPhysicians Total Care, Inc.2013-06-27Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralClinical Solutions Wholesale, Llc1990-09-30Not applicableUs
Propranolol Hydrochloridetablet80 mg/1oralbryant ranch prepack1986-05-13Not applicableUs
Propranolol Hydrochloridecapsule, extended release120 mg/1oralZydus Pharmaceuticals (USA) Inc.2014-04-15Not applicableUs
Propranolol Hydrochloridecapsule, extended release60 mg/1oralAvera Mc Kennan Hospital2015-03-11Not applicableUs
Propranolol Hydrochloridecapsule, extended release120 mg/1oralMylan Pharmaceuticals Inc.2007-02-15Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs
Propranolol Hydrochloridetablet80 mg/1oralHeritage Pharmaceuticals Inc.2008-10-13Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralREMEDYREPACK INC.2011-04-19Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1985-11-19Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralHeritage Pharmaceuticals Inc.2008-10-13Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralAphena Pharma Solutions Tennessee, Llc2010-06-21Not applicableUs
Propranolol Hydrochloridetablet20 mg/1oralA S Medication Solutions Llc2010-06-21Not applicableUs
Propranolol Hydrochloridecapsule, extended release120 mg/1oralBreckenridge Pharmaceutical, Inc.2013-03-11Not applicableUs
Propranolol Hydrochloridetablet80 mg/1oralMylan Pharmaceuticals Inc.1985-11-19Not applicableUs
Propranolol Hydrochloridetablet40 mg/1oralPhysicians Total Care, Inc.1996-12-09Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralCardinal Health2004-03-04Not applicableUs
Propranolol Hydrochloridetablet10 mg/1oralbryant ranch prepack2008-10-13Not applicableUs
Propranolol Hydrochloridecapsule, extended release60 mg/1oralCarilion Materials Management2007-08-10Not applicableUs
Propranolol Hyrochloridetablet10 mg/301oralNorthwind Pharmaceuticals2014-05-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AngilolNot Available
Bedranol SRNot Available
CardinolNot Available
CiplarNot Available
DeralinNot Available
DocitonNot Available
DuranolNot Available
InderalNot Available
IndoblocNot Available
INNOPRANNot Available
ProphyluxNot Available
SumialNot Available
Brand mixtures
NameLabellerIngredients
Inderide-40 TabWyeth Ayerst Canada Inc.
Inderide-80 TabWyeth Ayerst Canada Inc.
Propranolol Hydrochloride and HydrochlorothiazideMylan Pharmaceuticals Inc.
Propranolol ScopolamineTps
Salts
Name/CASStructureProperties
Propranolol Hydrochloride
318-98-9
Thumb
  • InChI Key: ZMRUPTIKESYGQW-UHFFFAOYNA-N
  • Monoisotopic Mass: 295.13390666
  • Average Mass: 295.804
DBSALT000549
Categories
UNII9Y8NXQ24VQ
CAS number525-66-6
WeightAverage: 259.3434
Monoisotopic: 259.157228921
Chemical FormulaC16H21NO2
InChI KeyInChIKey=AQHHHDLHHXJYJD-UHFFFAOYSA-N
InChI
InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
IUPAC Name
1-(naphthalen-1-yloxy)-3-[(propan-2-yl)amino]propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
KingdomOrganic compounds
Super ClassBenzenoids
ClassNaphthalenes
Sub ClassNot Available
Direct ParentNaphthalenes
Alternative Parents
Substituents
  • Naphthalene
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the prophylaxis of migraine.
PharmacodynamicsPropranolol, the prototype of the beta-adrenergic receptor antagonists, is a competitive, nonselective beta-blocker similar to nadolol without intrinsic sympathomimetic activity. Propanolol is a racemic compound; the l-isomer is responsible for adrenergic blocking activity.
Mechanism of actionPropranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension.
Related Articles
AbsorptionPropranolol is almost completely absorbed from the GI tract; however, plasma concentrations attained are quite variable among individuals.
Volume of distribution
  • 4 L
Protein bindingMore than 90%
Metabolism

Hepatic

SubstrateEnzymesProduct
Propranolol
N-desisopropylpropranololDetails
Propranolol
4'-hydroxypropanololDetails
Route of eliminationPropranolol is extensively metabolized with most metabolites appearing in the urine.
Half life4 hours
ClearanceNot Available
ToxicitySymptoms of overdose include bradycardia, cardiac failure, hypotension, and brochospasm. LD50=565 mg/kg (orally in mice).
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Propranolol Action PathwayDrug actionSMP00307
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9944
Blood Brain Barrier-0.9031
Caco-2 permeable+0.6942
P-glycoprotein substrateSubstrate0.7079
P-glycoprotein inhibitor IInhibitor0.5588
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6463
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.924
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8487
Ames testNon AMES toxic0.9392
CarcinogenicityNon-carcinogens0.9097
BiodegradationNot ready biodegradable0.9871
Rat acute toxicity2.5625 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9185
hERG inhibition (predictor II)Inhibitor0.7092
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Akrimax pharmaceuticals llc
  • Glaxosmithkline llc
  • Actavis elizabeth llc
  • Inwood laboratories inc sub forest laboratories inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical
  • Upsher smith laboratories inc
  • Roxane laboratories inc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hikma farmaceutica (portugal) sa
  • Sandoz canada inc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Morton grove pharmaceuticals inc
  • Wyeth ayerst laboratories
  • Clonmel healthcare ltd
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Interpharm inc
  • Ipca laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lederle laboratories div american cyanamid co
  • Mutual pharmaceutical co inc
  • Northstar healthcare holdings ltd
  • Par pharmaceutical inc
  • Pliva inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Schering corp sub schering plough corp
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals
  • Warner chilcott div warner lambert co
  • Warner chilcott inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral120 mg
Tabletoral20 mg
Tabletoral10 mg
Tabletoral40 mg
Tabletoral80 mg
Solutionoral4.28 mg/mL
Liquidintravenous1 mg
Capsule (sustained-release)oral120 mg
Capsule (sustained-release)oral160 mg
Capsule (sustained-release)oral60 mg
Capsule (sustained-release)oral80 mg
Capsule, extended releaseoral120 mg/1
Capsule, extended releaseoral160 mg/1
Capsule, extended releaseoral60 mg/1
Capsule, extended releaseoral80 mg/1
Injectionintravenous1 mg/mL
Injection, solutionintravenous1 mg/mL
Solutionoral20 mg/5mL
Solutionoral40 mg/5mL
Tabletoral10 mg/1
Tabletoral20 mg/1
Tabletoral40 mg/1
Tabletoral50 mg/1
Tabletoral60 mg/1
Tabletoral80 mg/1
Tabletoral
Solutionintravenous1 mg
Tabletoral10 mg/301
Prices
Unit descriptionCostUnit
Propranolol hcl powder11.63USD g
Propranolol 1 mg/ml vial10.0USD ml
Inderal la 160 mg capsule8.41USD capsule
Inderal LA 160 mg 24 Hour Capsule7.6USD capsule
Inderal la 160 mg capsule sa7.01USD capsule
Inderal la 120 mg capsule6.42USD capsule
Inderal LA 120 mg 24 Hour Capsule5.8USD capsule
Inderal la 120 mg capsule sa5.36USD capsule
Inderal la 80 mg capsule5.18USD capsule
Inderal LA 60 mg 24 Hour Capsule4.79USD capsule
Inderal LA 80 mg 24 Hour Capsule4.68USD capsule
Inderal la 60 mg capsule4.43USD capsule
Inderal la 80 mg capsule sa4.32USD capsule
Inderal la 60 mg capsule sa3.7USD capsule
Propranolol HCl CR 160 mg 24 Hour Capsule2.62USD capsule
InnoPran XL 80 mg 24 Hour Capsule2.5USD capsule
InnoPran XL 120 mg 24 Hour Capsule2.46USD capsule
Innopran xl 120 mg capsule2.41USD capsule
Innopran xl 80 mg capsule2.41USD capsule
Inderide 80-25 mg tablet2.17USD tablet
Propranolol HCl CR 120 mg 24 Hour Capsule2.0USD capsule
Inderide 40-25 mg tablet1.74USD tablet
Propranolol HCl CR 80 mg 24 Hour Capsule1.61USD capsule
Propranolol HCl CR 60 mg 24 Hour Capsule1.38USD capsule
Propranolol HCl 60 mg tablet1.27USD tablet
Inderal-La 160 mg Sustained-Release Capsule1.26USD capsule
Inderal-La 120 mg Sustained-Release Capsule1.07USD capsule
Inderal-La 80 mg Sustained-Release Capsule0.69USD capsule
Propranolol HCl 80 mg tablet0.66USD tablet
Propranolol-HCTZ 80-25 mg tablet0.65USD tablet
Inderal-La 60 mg Sustained-Release Capsule0.62USD capsule
Propranolol-HCTZ 40-25 mg tablet0.61USD tablet
Propranolol 80 mg tablet0.58USD tablet
Propranolol 60 mg tablet0.56USD tablet
Propranolol HCl 40 mg tablet0.53USD tablet
Propranolol 40 mg tablet0.45USD tablet
Propranolol HCl 20 mg tablet0.36USD tablet
Propranolol 20 mg tablet0.33USD tablet
Apo-Propranolol 120 mg Tablet0.32USD tablet
Propranolol HCl 10 mg tablet0.29USD tablet
Propranolol 10 mg tablet0.22USD tablet
Propranolol HCl 20 mg/5ml Solution0.11USD ml
Apo-Propranolol 80 mg Tablet0.06USD tablet
Novo-Pranol 80 mg Tablet0.06USD tablet
Pms-Propranolol 80 mg Tablet0.06USD tablet
Apo-Propranolol 20 mg Tablet0.04USD tablet
Apo-Propranolol 40 mg Tablet0.04USD tablet
Novo-Pranol 20 mg Tablet0.04USD tablet
Novo-Pranol 40 mg Tablet0.04USD tablet
Apo-Propranolol 10 mg Tablet0.02USD tablet
Novo-Pranol 10 mg Tablet0.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6500454 No2001-10-042021-10-04Us
US8338489 No2008-10-162028-10-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point96 °CPhysProp
water solubility61.7 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP3.48AVDEEF,A (1997)
Caco2 permeability-4.58ADME Research, USCD
pKa9.42SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0794 mg/mLALOGPS
logP3.03ALOGPS
logP2.58ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area41.49 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity76.83 m3·mol-1ChemAxon
Polarizability29.98 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-03di-0090000000-f8c39664b694f5784865View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-05fr-9000000000-84923a2dc3053801527aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-0fk9-2932000000-fa245a17a643ef33a0b2View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positivesplash10-03di-0090000000-ee9d9c871e322202a948View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positivesplash10-03di-0290000000-9f3f72a6b6b792659137View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positivesplash10-0avi-5900000000-95293e6a5f843d0cc282View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positivesplash10-0ab9-9700000000-6b5b9e9743cb3f7bca58View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positivesplash10-0adi-9700000000-f5825268222d45a4ce95View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0159-1900000000-9872255282c6a95633aaView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-00di-9500000000-122203085c028de6cbe4View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0aor-0900000000-39e75b6ae19b4763a0bfView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-004i-0900000000-b75e7bf7aa20ce854157View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-00di-9200000000-2f102916e2fe0f6c1f4bView in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

DrugSyn.org

US3520919
General References
  1. Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK: Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008 May;42(6):503-6. Epub 2007 Jun 22. [PubMed:17588604 ]
  2. Ohnishi ST, Sadanaga KK, Katsuoka M, Weidanz WP: Effects of membrane acting-drugs on plasmodium species and sickle cell erythrocytes. Mol Cell Biochem. 1989 Nov 23-Dec 19;91(1-2):159-65. [PubMed:2695829 ]
  3. Singh N, Puri SK: Interaction between chloroquine and diverse pharmacological agents in chloroquine resistant Plasmodium yoelii nigeriensis. Acta Trop. 2000 Nov 2;77(2):185-93. [PubMed:11080509 ]
  4. Murphy SC, Harrison T, Hamm HE, Lomasney JW, Mohandas N, Haldar K: Erythrocyte G protein as a novel target for malarial chemotherapy. PLoS Med. 2006 Dec;3(12):e528. [PubMed:17194200 ]
External Links
ATC CodesC07BA05C07AA05C07FA05
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelDownload (256 KB)
MSDSDownload (74.7 KB)
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Propranolol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Propranolol.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Propranolol.
AbirateroneThe serum concentration of Propranolol can be increased when it is combined with Abiraterone.
AcebutololPropranolol may increase the hypotensive activities of Acebutolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Propranolol.
AcepromazineAcepromazine may increase the hypotensive activities of Propranolol.
AcetaminophenThe serum concentration of Propranolol can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Propranolol is combined with Acetazolamide.
AcetohexamidePropranolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Propranolol is combined with Acetylcholine.
AcetyldigitoxinPropranolol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Propranolol.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Propranolol.
AdapaleneAdapalene may decrease the antihypertensive activities of Propranolol.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Propranolol.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Propranolol.
AlbendazoleThe serum concentration of Propranolol can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Propranolol.
AldosteroneThe serum concentration of Propranolol can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Propranolol.
AlectinibThe serum concentration of Propranolol can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Propranolol can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Propranolol.
AlfuzosinPropranolol may increase the orthostatic hypotensive activities of Alfuzosin.
AlimemazineAlimemazine may increase the hypotensive activities of Propranolol.
AliskirenPropranolol may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Propranolol.
AlprenololPropranolol may increase the hypotensive activities of Alprenolol.
AmantadineThe serum concentration of Propranolol can be increased when it is combined with Amantadine.
AmbenoniumAmbenonium may increase the bradycardic activities of Propranolol.
AmbrisentanPropranolol may increase the hypotensive activities of Ambrisentan.
AmifostinePropranolol may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Propranolol is combined with Amiloride.
Aminohippuric acidThe serum concentration of Propranolol can be increased when it is combined with Aminohippuric acid.
AminophyllinePropranolol may decrease the bronchodilatory activities of Aminophylline.
AmiodaroneAmiodarone may increase the bradycardic activities of Propranolol.
AmitriptylineThe serum concentration of Propranolol can be increased when it is combined with Amitriptyline.
AmlodipineAmlodipine may increase the hypotensive activities of Propranolol.
AmobarbitalAmobarbital may increase the hypotensive activities of Propranolol.
AmodiaquineThe metabolism of Propranolol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Propranolol can be increased when it is combined with Amoxapine.
AmprenavirThe serum concentration of Propranolol can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Propranolol can be increased when it is combined with Amsacrine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Propranolol is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the antihypertensive activities of Propranolol.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Propranolol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Propranolol.
ApraclonidineThe risk or severity of adverse effects can be increased when Propranolol is combined with Apraclonidine.
ApremilastApremilast may decrease the antihypertensive activities of Propranolol.
AprepitantThe serum concentration of Propranolol can be increased when it is combined with Aprepitant.
ArbutaminePropranolol may decrease the bronchodilatory activities of Arbutamine.
ArecolineThe risk or severity of adverse effects can be increased when Propranolol is combined with Arecoline.
ArformoterolPropranolol may decrease the bronchodilatory activities of Arformoterol.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Propranolol.
AripiprazoleAripiprazole may increase the hypotensive activities of Propranolol.
ArmodafinilThe metabolism of Propranolol can be decreased when combined with Armodafinil.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Propranolol.
ArtemetherThe metabolism of Propranolol can be decreased when combined with Artemether.
AstemizoleThe serum concentration of Propranolol can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Propranolol.
AtenololAtenolol may increase the hypotensive activities of Propranolol.
AtomoxetineThe metabolism of Propranolol can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Propranolol can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Propranolol.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Propranolol.
AzelastineAzelastine may decrease the antihypertensive activities of Propranolol.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Propranolol is combined with Azilsartan medoxomil.
AzithromycinThe serum concentration of Propranolol can be increased when it is combined with Azithromycin.
BalsalazideBalsalazide may decrease the antihypertensive activities of Propranolol.
BambuterolPropranolol may decrease the bronchodilatory activities of Bambuterol.
BarbitalBarbital may increase the hypotensive activities of Propranolol.
BenazeprilBenazepril may increase the hypotensive activities of Propranolol.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Propranolol.
BenmoxinBenmoxin may increase the hypotensive activities of Propranolol.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Propranolol.
BenzocaineThe serum concentration of Propranolol can be increased when it is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Propranolol.
BepridilPropranolol may increase the hypotensive activities of Bepridil.
BeractantPropranolol may increase the bradycardic activities of Beractant.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Propranolol.
BetaxololBetaxolol may increase the hypotensive activities of Propranolol.
BethanecholThe risk or severity of adverse effects can be increased when Propranolol is combined with Bethanechol.
BethanidineBethanidine may increase the hypotensive activities of Propranolol.
BexaroteneThe serum concentration of Propranolol can be decreased when it is combined with Bexarotene.
BimatoprostPropranolol may increase the hypotensive activities of Bimatoprost.
BiperidenThe serum concentration of Propranolol can be increased when it is combined with Biperiden.
BisoprololPropranolol may increase the hypotensive activities of Bisoprolol.
BoceprevirThe metabolism of Propranolol can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Propranolol.
BortezomibThe metabolism of Propranolol can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Propranolol can be decreased when it is combined with Bosentan.
BosentanPropranolol may increase the hypotensive activities of Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Propranolol.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Propranolol.
BretyliumBretylium may increase the bradycardic activities of Propranolol.
BretyliumPropranolol may increase the hypotensive activities of Bretylium.
BrimonidinePropranolol may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Propranolol.
BromfenacBromfenac may decrease the antihypertensive activities of Propranolol.
BromocriptineThe serum concentration of Propranolol can be increased when it is combined with Bromocriptine.
BumetanideThe risk or severity of adverse effects can be increased when Propranolol is combined with Bumetanide.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Propranolol.
BupranololPropranolol may increase the hypotensive activities of Bupranolol.
BuprenorphineThe serum concentration of Propranolol can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Propranolol can be decreased when combined with Bupropion.
BuspironeThe serum concentration of Propranolol can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Propranolol.
CabergolinePropranolol may increase the vasoconstricting activities of Cabergoline.
CaffeineThe serum concentration of Propranolol can be increased when it is combined with Caffeine.
CalfactantPropranolol may increase the bradycardic activities of Calfactant.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Propranolol.
CanagliflozinThe risk or severity of adverse effects can be increased when Propranolol is combined with Canagliflozin.
CandesartanPropranolol may increase the hypotensive activities of Candesartan.
CandoxatrilPropranolol may increase the hypotensive activities of Candoxatril.
CaptoprilPropranolol may increase the hypotensive activities of Captopril.
CarbacholThe risk or severity of adverse effects can be increased when Propranolol is combined with Carbachol.
CarbamazepineThe serum concentration of Propranolol can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Propranolol.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Propranolol.
CaroxazoneCaroxazone may increase the hypotensive activities of Propranolol.
CarprofenCarprofen may decrease the antihypertensive activities of Propranolol.
CarteololCarteolol may increase the hypotensive activities of Propranolol.
CarvedilolPropranolol may increase the hypotensive activities of Carvedilol.
CaspofunginThe serum concentration of Propranolol can be increased when it is combined with Caspofungin.
CastanospermineCastanospermine may decrease the antihypertensive activities of Propranolol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Propranolol.
CeliprololCeliprolol may increase the hypotensive activities of Propranolol.
CeliprololPropranolol may decrease the bronchodilatory activities of Celiprolol.
CeritinibPropranolol may increase the bradycardic activities of Ceritinib.
CeritinibThe serum concentration of Propranolol can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Propranolol.
CevimelineThe risk or severity of adverse effects can be increased when Propranolol is combined with Cevimeline.
ChloramphenicolThe metabolism of Propranolol can be decreased when combined with Chloramphenicol.
ChloroquineChloroquine may decrease the antihypertensive activities of Propranolol.
ChlorothiazidePropranolol may increase the hypotensive activities of Chlorothiazide.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Propranolol.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Propranolol.
ChlorpropamidePropranolol may increase the hypoglycemic activities of Chlorpropamide.
ChlorpropamideThe serum concentration of Propranolol can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Propranolol can be increased when it is combined with Chlorprothixene.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Propranolol.
CholecalciferolThe metabolism of Propranolol can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Propranolol can be increased when it is combined with Cholesterol.
CholestyramineThe serum concentration of Propranolol can be decreased when it is combined with Cholestyramine.
Cholic AcidThe serum concentration of Propranolol can be decreased when it is combined with Cholic Acid.
CilazaprilPropranolol may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Propranolol can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Propranolol.
CinacalcetThe metabolism of Propranolol can be decreased when combined with Cinacalcet.
CiprofloxacinThe serum concentration of Propranolol can be increased when it is combined with Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Propranolol.
CitalopramThe serum concentration of Propranolol can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Propranolol can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Propranolol can be decreased when combined with Clemastine.
ClenbuterolPropranolol may decrease the bronchodilatory activities of Clenbuterol.
ClevidipineThe risk or severity of adverse effects can be increased when Propranolol is combined with Clevidipine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Propranolol.
ClobazamThe metabolism of Propranolol can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Propranolol can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Propranolol.
ClomipramineThe serum concentration of Propranolol can be increased when it is combined with Clomipramine.
ClonidinePropranolol may increase the hypotensive activities of Clonidine.
ClonixinClonixin may decrease the antihypertensive activities of Propranolol.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Propranolol.
ClotrimazoleThe metabolism of Propranolol can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Propranolol.
ClozapineThe metabolism of Propranolol can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Propranolol can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Propranolol.
CocaineThe metabolism of Propranolol can be decreased when combined with Cocaine.
ColchicineThe serum concentration of Propranolol can be increased when it is combined with Colchicine.
ColesevelamThe serum concentration of Propranolol can be decreased when it is combined with Colesevelam.
ColestipolThe serum concentration of Propranolol can be decreased when it is combined with Colestipol.
ColforsinThe serum concentration of Propranolol can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Propranolol can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Propranolol.
CoumaphosCoumaphos may increase the bradycardic activities of Propranolol.
CrizotinibThe metabolism of Propranolol can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Propranolol.
CryptenaminePropranolol may increase the hypotensive activities of Cryptenamine.
CyclophosphamideThe serum concentration of Propranolol can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Propranolol can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Propranolol.
CyclothiazidePropranolol may increase the hypotensive activities of Cyclothiazide.
Cyproterone acetateThe serum concentration of Propranolol can be decreased when it is combined with Cyproterone acetate.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Propranolol.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Propranolol.
DabrafenibThe serum concentration of Propranolol can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Propranolol.
DaclatasvirThe serum concentration of Propranolol can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Propranolol can be increased when it is combined with Dactinomycin.
DapagliflozinThe risk or severity of adverse effects can be increased when Propranolol is combined with Dapagliflozin.
DapoxetineThe serum concentration of Propranolol can be increased when it is combined with Dapoxetine.
DarifenacinThe metabolism of Propranolol can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Propranolol can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Propranolol can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Propranolol can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Propranolol.
DebrisoquinPropranolol may increase the hypotensive activities of Debrisoquin.
DecamethoniumDecamethonium may increase the bradycardic activities of Propranolol.
DeferasiroxThe serum concentration of Propranolol can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Propranolol can be decreased when combined with Delavirdine.
DemecariumDemecarium may increase the bradycardic activities of Propranolol.
DeserpidinePropranolol may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Propranolol can be increased when it is combined with Desipramine.
DeslanosidePropranolol may increase the bradycardic activities of Deslanoside.
DesloratadineThe serum concentration of Propranolol can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Propranolol can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Propranolol.
DexmedetomidineThe risk or severity of adverse effects can be increased when Propranolol is combined with Dexmedetomidine.
DextromethorphanThe serum concentration of Propranolol can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Propranolol.
DiazoxideDiazoxide may increase the hypotensive activities of Propranolol.
DichlorvosDichlorvos may increase the bradycardic activities of Propranolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Propranolol.
DiclofenamideThe risk or severity of adverse effects can be increased when Propranolol is combined with Diclofenamide.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Propranolol.
DiflunisalDiflunisal may decrease the antihypertensive activities of Propranolol.
DigitoxinPropranolol may increase the bradycardic activities of Digitoxin.
DigoxinPropranolol may increase the bradycardic activities of Digoxin.
DigoxinThe serum concentration of Propranolol can be decreased when it is combined with Digoxin.
DihydroergotaminePropranolol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineThe metabolism of Propranolol can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Propranolol.
DiltiazemDiltiazem may increase the hypotensive activities of Propranolol.
DinutuximabThe risk or severity of adverse effects can be increased when Propranolol is combined with Dinutuximab.
DiphenhydramineThe metabolism of Propranolol can be decreased when combined with Diphenhydramine.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Propranolol.
DipivefrinPropranolol may decrease the bronchodilatory activities of Dipivefrin.
DipyridamoleDipyridamole may increase the bradycardic activities of Propranolol.
DipyridamoleThe risk or severity of adverse effects can be increased when Propranolol is combined with Dipyridamole.
DisopyramideDisopyramide may increase the bradycardic activities of Propranolol.
DobutaminePropranolol may decrease the bronchodilatory activities of Dobutamine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Propranolol.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Propranolol.
DonepezilDonepezil may increase the bradycardic activities of Propranolol.
DorzolamidePropranolol may increase the hypotensive activities of Dorzolamide.
DoxazosinPropranolol may increase the hypotensive activities of Doxazosin.
DoxepinThe serum concentration of Propranolol can be increased when it is combined with Doxepin.
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Propranolol.
DoxorubicinThe serum concentration of Propranolol can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Propranolol.
DoxycyclineThe metabolism of Propranolol can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Propranolol can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Propranolol can be decreased when combined with Dronedarone.
DronedaronePropranolol may increase the bradycardic activities of Dronedarone.
DroxicamDroxicam may decrease the antihypertensive activities of Propranolol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Propranolol.
DroxidopaPropranolol may decrease the bronchodilatory activities of Droxidopa.
DuloxetinePropranolol may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe metabolism of Propranolol can be decreased when combined with Duloxetine.
DyphyllinePropranolol may decrease the bronchodilatory activities of Dyphylline.
EchothiophateEchothiophate may increase the bradycardic activities of Propranolol.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Propranolol.
EdrophoniumEdrophonium may increase the bradycardic activities of Propranolol.
EfavirenzThe serum concentration of Propranolol can be decreased when it is combined with Efavirenz.
EfonidipinePropranolol may increase the hypotensive activities of Efonidipine.
ElbasvirThe serum concentration of Propranolol can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Propranolol.
EliglustatThe metabolism of Propranolol can be decreased when combined with Eliglustat.
EmpagliflozinThe risk or severity of adverse effects can be increased when Propranolol is combined with Empagliflozin.
EnalaprilPropranolol may increase the hypotensive activities of Enalapril.
EnalaprilatPropranolol may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Propranolol can be increased when it is combined with Enzalutamide.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Propranolol.
EphedraPropranolol may decrease the bronchodilatory activities of Ephedra.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Propranolol is combined with EPIBATIDINE.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Propranolol.
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Propranolol.
EpinephrinePropranolol may decrease the bronchodilatory activities of Epinephrine.
EpirizoleEpirizole may decrease the antihypertensive activities of Propranolol.
EplerenoneThe risk or severity of adverse effects can be increased when Propranolol is combined with Eplerenone.
EpoprostenolPropranolol may increase the hypotensive activities of Epoprostenol.
EprosartanPropranolol may increase the hypotensive activities of Eprosartan.
Ergoloid mesylatePropranolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovinePropranolol may increase the vasoconstricting activities of Ergonovine.
ErgonovineThe serum concentration of Propranolol can be increased when it is combined with Ergonovine.
ErgotaminePropranolol may increase the vasoconstricting activities of Ergotamine.
ErgotamineThe serum concentration of Propranolol can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Propranolol.
ErythromycinThe metabolism of Propranolol can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Propranolol.
Eslicarbazepine acetateThe serum concentration of Propranolol can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Propranolol.
EsomeprazoleThe metabolism of Propranolol can be decreased when combined with Esomeprazole.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Propranolol.
EstramustineThe serum concentration of Propranolol can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Propranolol can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Propranolol.
EstroneThe serum concentration of Propranolol can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Propranolol.
Etacrynic acidThe risk or severity of adverse effects can be increased when Propranolol is combined with Etacrynic acid.
EtanerceptEtanercept may decrease the antihypertensive activities of Propranolol.
EthanolThe serum concentration of Propranolol can be decreased when it is combined with Ethanol.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Propranolol.
EtodolacEtodolac may decrease the antihypertensive activities of Propranolol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Propranolol.
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Propranolol.
EtoperidoneThe serum concentration of Propranolol can be increased when it is combined with Etoperidone.
EtoposideThe serum concentration of Propranolol can be increased when it is combined with Etoposide.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Propranolol.
EtravirineThe serum concentration of Propranolol can be decreased when it is combined with Etravirine.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Propranolol.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Propranolol.
exisulindexisulind may decrease the antihypertensive activities of Propranolol.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Propranolol.
FelodipinePropranolol may increase the hypotensive activities of Felodipine.
FenbufenFenbufen may decrease the antihypertensive activities of Propranolol.
FenfluramineThe serum concentration of Propranolol can be increased when it is combined with Fenfluramine.
FenoldopamPropranolol may increase the hypotensive activities of Fenoldopam.
FenoprofenFenoprofen may decrease the antihypertensive activities of Propranolol.
FenoterolPropranolol may decrease the bronchodilatory activities of Fenoterol.
FentanylThe serum concentration of Propranolol can be increased when it is combined with Fentanyl.
FenthionFenthion may increase the bradycardic activities of Propranolol.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propranolol.
FexofenadineThe serum concentration of Propranolol can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Propranolol.
FingolimodPropranolol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Propranolol.
FluconazoleThe metabolism of Propranolol can be decreased when combined with Fluconazole.
FlunixinFlunixin may decrease the antihypertensive activities of Propranolol.
FluoxetineThe serum concentration of Propranolol can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Propranolol can be increased when it is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Propranolol.
FlurazepamThe serum concentration of Propranolol can be increased when it is combined with Flurazepam.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Propranolol.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Propranolol.
FluvoxamineThe metabolism of Propranolol can be decreased when combined with Fluvoxamine.
FormoterolPropranolol may decrease the bronchodilatory activities of Formoterol.
FosamprenavirThe metabolism of Propranolol can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Propranolol can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Propranolol.
FosphenytoinThe metabolism of Propranolol can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Propranolol.
FurosemideThe risk or severity of adverse effects can be increased when Propranolol is combined with Furosemide.
Fusidic AcidThe serum concentration of Propranolol can be increased when it is combined with Fusidic Acid.
GalantamineGalantamine may increase the bradycardic activities of Propranolol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Propranolol.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Propranolol.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Propranolol.
GemfibrozilThe metabolism of Propranolol can be decreased when combined with Gemfibrozil.
GenisteinThe serum concentration of Propranolol can be increased when it is combined with Genistein.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Propranolol.
GlibornuridePropranolol may increase the hypoglycemic activities of Glibornuride.
GliclazidePropranolol may increase the hypoglycemic activities of Gliclazide.
GlimepiridePropranolol may increase the hypoglycemic activities of Glimepiride.
GlipizidePropranolol may increase the hypoglycemic activities of Glipizide.
GliquidonePropranolol may increase the hypoglycemic activities of Gliquidone.
GlisoxepidePropranolol may increase the hypoglycemic activities of Glisoxepide.
GlyburidePropranolol may increase the hypoglycemic activities of Glyburide.
GlyburideThe serum concentration of Propranolol can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Propranolol can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Propranolol can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Propranolol.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Propranolol.
GTS-21The risk or severity of adverse effects can be increased when Propranolol is combined with GTS-21.
GuanabenzPropranolol may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Propranolol.
GuanethidinePropranolol may increase the hypotensive activities of Guanethidine.
GuanfacinePropranolol may increase the hypotensive activities of Guanfacine.
HaloperidolThe serum concentration of Propranolol can be increased when it is combined with Haloperidol.
HexamethoniumPropranolol may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Propranolol.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Propranolol.
Huperzine AHuperzine A may increase the bradycardic activities of Propranolol.
HydracarbazineHydracarbazine may increase the hypotensive activities of Propranolol.
HydralazinePropranolol may increase the hypotensive activities of Hydralazine.
HydrochlorothiazidePropranolol may increase the hypotensive activities of Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Propranolol can be increased when it is combined with Hydrocortisone.
HydroflumethiazidePropranolol may increase the hypotensive activities of Hydroflumethiazide.
HydroxychloroquineThe metabolism of Propranolol can be decreased when combined with Hydroxychloroquine.
IbuprofenIbuprofen may decrease the antihypertensive activities of Propranolol.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Propranolol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Propranolol.
IcatibantIcatibant may decrease the antihypertensive activities of Propranolol.
IdelalisibThe serum concentration of Propranolol can be increased when it is combined with Idelalisib.
IloprostIloprost may increase the hypotensive activities of Propranolol.
ImatinibThe metabolism of Propranolol can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Propranolol.
ImipramineThe serum concentration of Propranolol can be increased when it is combined with Imipramine.
IndacaterolPropranolol may decrease the bronchodilatory activities of Indacaterol.
IndalpineThe serum concentration of Propranolol can be increased when it is combined with Indalpine.
IndapamidePropranolol may increase the hypotensive activities of Indapamide.
IndenololPropranolol may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Propranolol can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Propranolol.
IndomethacinIndomethacin may decrease the antihypertensive activities of Propranolol.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Propranolol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Propranolol.
IndoraminPropranolol may increase the hypotensive activities of Indoramin.
Insulin PorkPropranolol may increase the hypoglycemic activities of Insulin Pork.
IproclozideIproclozide may increase the hypotensive activities of Propranolol.
IproniazidIproniazid may increase the hypotensive activities of Propranolol.
IrbesartanPropranolol may increase the hypotensive activities of Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Propranolol.
IsavuconazoniumThe metabolism of Propranolol can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Propranolol.
IsoetarinePropranolol may decrease the bronchodilatory activities of Isoetarine.
IsoflurophateIsoflurophate may increase the bradycardic activities of Propranolol.
IsoniazidThe metabolism of Propranolol can be decreased when combined with Isoniazid.
IsoprenalinePropranolol may decrease the bronchodilatory activities of Isoprenaline.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Propranolol is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Propranolol is combined with Isosorbide Mononitrate.
IsoxicamIsoxicam may decrease the antihypertensive activities of Propranolol.
IsoxsuprineThe risk or severity of adverse effects can be increased when Propranolol is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Propranolol.
ItraconazoleThe serum concentration of Propranolol can be increased when it is combined with Itraconazole.
IvabradinePropranolol may increase the bradycardic activities of Ivabradine.
IvacaftorThe serum concentration of Propranolol can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Propranolol can be increased when it is combined with Ivermectin.
KebuzoneKebuzone may decrease the antihypertensive activities of Propranolol.
KetamineThe serum concentration of Propranolol can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Propranolol.
KetoconazoleThe serum concentration of Propranolol can be increased when it is combined with Ketoconazole.
KetoprofenKetoprofen may decrease the antihypertensive activities of Propranolol.
KetorolacKetorolac may decrease the antihypertensive activities of Propranolol.
LabetalolPropranolol may increase the hypotensive activities of Labetalol.
LacidipinePropranolol may increase the hypotensive activities of Lacidipine.
LacosamidePropranolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Propranolol.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Propranolol.
LanreotidePropranolol may increase the bradycardic activities of Lanreotide.
LansoprazoleThe serum concentration of Propranolol can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Propranolol can be increased when it is combined with Lapatinib.
LatanoprostPropranolol may increase the hypotensive activities of Latanoprost.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Propranolol.
LeflunomideLeflunomide may decrease the antihypertensive activities of Propranolol.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Propranolol.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Propranolol.
LercanidipineLercanidipine may increase the hypotensive activities of Propranolol.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Propranolol.
LevobunololThe risk or severity of adverse effects can be increased when Propranolol is combined with Levobunolol.
LevodopaPropranolol may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Propranolol can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Propranolol can be increased when it is combined with Levomilnacipran.
LevothyroxineThe serum concentration of Propranolol can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Propranolol.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Propranolol.
LiothyronineThe serum concentration of Propranolol can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Propranolol can be decreased when it is combined with Liotrix.
LisinoprilPropranolol may increase the hypotensive activities of Lisinopril.
LobelineThe risk or severity of adverse effects can be increased when Propranolol is combined with Lobeline.
LofexidinePropranolol may increase the hypotensive activities of Lofexidine.
LomitapideThe serum concentration of Propranolol can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Propranolol can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Propranolol can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Propranolol can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Propranolol can be decreased when combined with Lorcaserin.
LornoxicamLornoxicam may decrease the antihypertensive activities of Propranolol.
LosartanPropranolol may increase the hypotensive activities of Losartan.
LovastatinThe metabolism of Propranolol can be decreased when combined with Lovastatin.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Propranolol.
Lu AA21004The serum concentration of Propranolol can be increased when it is combined with Lu AA21004.
LucinactantPropranolol may increase the bradycardic activities of Lucinactant.
LuliconazoleThe serum concentration of Propranolol can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Propranolol can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Propranolol can be decreased when combined with Lumefantrine.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Propranolol.
MacitentanPropranolol may increase the hypotensive activities of Macitentan.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Propranolol.
MalathionMalathion may increase the bradycardic activities of Propranolol.
ManidipinePropranolol may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Propranolol is combined with Mannitol.
MaprotilineThe serum concentration of Propranolol can be increased when it is combined with Maprotiline.
MasoprocolMasoprocol may decrease the antihypertensive activities of Propranolol.
MebanazineMebanazine may increase the hypotensive activities of Propranolol.
MebendazoleThe serum concentration of Propranolol can be increased when it is combined with Mebendazole.
MecamylaminePropranolol may increase the hypotensive activities of Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Propranolol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Propranolol.
MefloquineMefloquine may increase the bradycardic activities of Propranolol.
Megestrol acetateThe serum concentration of Propranolol can be increased when it is combined with Megestrol acetate.
MeloxicamMeloxicam may decrease the antihypertensive activities of Propranolol.
MemantineMemantine may increase the bradycardic activities of Propranolol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Propranolol.
MeprobamateThe serum concentration of Propranolol can be increased when it is combined with Meprobamate.
MesalazineMesalazine may decrease the antihypertensive activities of Propranolol.
MesoridazineMesoridazine may increase the hypotensive activities of Propranolol.
MetamizoleMetamizole may decrease the antihypertensive activities of Propranolol.
MethacholineThe risk or severity of adverse effects can be increased when Propranolol is combined with Methacholine.
MethadoneThe serum concentration of Propranolol can be increased when it is combined with Methadone.
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Propranolol.
MethazolamideThe risk or severity of adverse effects can be increased when Propranolol is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Propranolol.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Propranolol.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Propranolol.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Propranolol.
MethyldopaPropranolol may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Propranolol.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Propranolol.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Propranolol.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Propranolol.
MetipranololPropranolol may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Propranolol.
MetoprololMetoprolol may increase the hypotensive activities of Propranolol.
MexiletineThe metabolism of Propranolol can be decreased when combined with Mexiletine.
MibefradilPropranolol may increase the hypotensive activities of Mibefradil.
MiconazoleThe serum concentration of Propranolol can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Propranolol can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Propranolol.
MidodrinePropranolol may increase the bradycardic activities of Midodrine.
MifepristoneThe metabolism of Propranolol can be decreased when combined with Mifepristone.
MilnacipranThe serum concentration of Propranolol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Propranolol.
MinoxidilMinoxidil may increase the hypotensive activities of Propranolol.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Propranolol.
MirabegronThe metabolism of Propranolol can be decreased when combined with Mirabegron.
MitomycinThe serum concentration of Propranolol can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Propranolol can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Propranolol can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Propranolol.
MoclobemideMoclobemide may increase the hypotensive activities of Propranolol.
ModafinilThe serum concentration of Propranolol can be decreased when it is combined with Modafinil.
MoexiprilPropranolol may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Propranolol.
MoricizineMoricizine may increase the hypotensive activities of Propranolol.
MorphineThe serum concentration of Propranolol can be increased when it is combined with Morphine.
MoxonidinePropranolol may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Propranolol.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Propranolol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Propranolol.
NabumetoneNabumetone may decrease the antihypertensive activities of Propranolol.
NadololPropranolol may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Propranolol can be decreased when it is combined with Nafcillin.
NaftifineNaftifine may decrease the antihypertensive activities of Propranolol.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Propranolol.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Propranolol.
NaltrexoneThe serum concentration of Propranolol can be increased when it is combined with Naltrexone.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Propranolol.
NaproxenNaproxen may decrease the antihypertensive activities of Propranolol.
NaringeninThe serum concentration of Propranolol can be increased when it is combined with Naringenin.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Propranolol.
NebivololPropranolol may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Propranolol can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Propranolol can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Propranolol.
NeostigmineNeostigmine may increase the bradycardic activities of Propranolol.
NepafenacNepafenac may decrease the antihypertensive activities of Propranolol.
NesiritideThe risk or severity of adverse effects can be increased when Propranolol is combined with Nesiritide.
NetupitantThe serum concentration of Propranolol can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Propranolol can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Propranolol.
NicardipinePropranolol may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Propranolol.
NicotineThe risk or severity of adverse effects can be increased when Propranolol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Propranolol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Propranolol.
NifedipineThe risk or severity of adverse effects can be increased when Propranolol is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Propranolol.
NiguldipinePropranolol may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Propranolol can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Propranolol.
NilvadipinePropranolol may increase the hypotensive activities of Nilvadipine.
NimesulideNimesulide may decrease the antihypertensive activities of Propranolol.
NimodipineNimodipine may increase the hypotensive activities of Propranolol.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Propranolol.
NisoldipineNisoldipine may increase the hypotensive activities of Propranolol.
NitrazepamThe serum concentration of Propranolol can be increased when it is combined with Nitrazepam.
NitrendipinePropranolol may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Propranolol is combined with Nitroglycerin.
NitroprussideNitroprusside may increase the hypotensive activities of Propranolol.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Propranolol.
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Propranolol.
NorepinephrinePropranolol may decrease the bronchodilatory activities of Norepinephrine.
NorethisteroneThe serum concentration of Propranolol can be decreased when it is combined with Norethisterone.
ObinutuzumabPropranolol may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Propranolol.
OctreotideOctreotide may increase the bradycardic activities of Propranolol.
OlanzapineThe serum concentration of Propranolol can be increased when it is combined with Olanzapine.
OlaparibThe metabolism of Propranolol can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Propranolol.
OlodaterolPropranolol may decrease the bronchodilatory activities of Olodaterol.
OlopatadineOlopatadine may decrease the antihypertensive activities of Propranolol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Propranolol.
OmapatrilatPropranolol may increase the hypotensive activities of Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Propranolol.
OmeprazoleThe serum concentration of Propranolol can be increased when it is combined with Omeprazole.
OrciprenalinePropranolol may decrease the bronchodilatory activities of Orciprenaline.
OrgoteinOrgotein may decrease the antihypertensive activities of Propranolol.
OsimertinibThe serum concentration of Propranolol can be increased when it is combined with Osimertinib.
OuabainPropranolol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Propranolol.
OxprenololPropranolol may increase the hypotensive activities of Oxprenolol.
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Propranolol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Propranolol.
P-NitrophenolThe serum concentration of Propranolol can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Propranolol can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Propranolol can be increased when it is combined with Palbociclib.
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Propranolol.
Palmitic AcidThe serum concentration of Propranolol can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Propranolol.
PanobinostatThe metabolism of Propranolol can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Propranolol can be increased when it is combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Propranolol is combined with Papaverine.
ParecoxibParecoxib may decrease the antihypertensive activities of Propranolol.
PargylinePropranolol may increase the hypotensive activities of Pargyline.
ParoxetineThe serum concentration of Propranolol can be increased when it is combined with Paroxetine.
PasireotidePropranolol may increase the bradycardic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Propranolol.
Peginterferon alfa-2bThe serum concentration of Propranolol can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololPropranolol may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Propranolol.
PentoliniumPropranolol may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Propranolol.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Propranolol.
PerindoprilPropranolol may increase the hypotensive activities of Perindopril.
PerphenazinePerphenazine may increase the hypotensive activities of Propranolol.
PhenelzinePhenelzine may increase the hypotensive activities of Propranolol.
PheniprazinePheniprazine may increase the hypotensive activities of Propranolol.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Propranolol.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Propranolol.
PhenoxybenzaminePropranolol may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Propranolol.
PhentolaminePropranolol may increase the hypotensive activities of Phentolamine.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Propranolol.
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Propranolol.
PhenylpropanolaminePropranolol may decrease the bronchodilatory activities of Phenylpropanolamine.
PhenytoinThe metabolism of Propranolol can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Propranolol.
PhysostigminePhysostigmine may increase the bradycardic activities of Propranolol.
PilocarpineThe risk or severity of adverse effects can be increased when Propranolol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Propranolol.
PimozideThe serum concentration of Propranolol can be increased when it is combined with Pimozide.
PinacidilPropranolol may increase the hypotensive activities of Pinacidil.
PindololPropranolol may increase the hypotensive activities of Pindolol.
PirbuterolPropranolol may decrease the bronchodilatory activities of Pirbuterol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Propranolol.
PirlindolePirlindole may increase the hypotensive activities of Propranolol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Propranolol.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Propranolol.
PivhydrazinePivhydrazine may increase the hypotensive activities of Propranolol.
Platelet Activating FactorThe serum concentration of Propranolol can be decreased when it is combined with Platelet Activating Factor.
PolythiazidePropranolol may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Propranolol.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Propranolol.
Poractant alfaPropranolol may increase the bradycardic activities of Poractant alfa.
PosaconazoleThe serum concentration of Propranolol can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Propranolol.
PrazosinPrazosin may increase the hypotensive activities of Propranolol.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Propranolol.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Propranolol.
PrimaquineThe metabolism of Propranolol can be decreased when combined with Primaquine.
PrimidonePrimidone may increase the hypotensive activities of Propranolol.
ProbenecidThe serum concentration of Propranolol can be increased when it is combined with Probenecid.
ProcaterolPropranolol may decrease the bronchodilatory activities of Procaterol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Propranolol.
ProgesteroneThe serum concentration of Propranolol can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Propranolol.
PromazinePromazine may increase the hypotensive activities of Propranolol.
PromethazinePromethazine may increase the hypotensive activities of Propranolol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Propranolol.
PropafenoneThe serum concentration of Propranolol can be increased when it is combined with Propafenone.
PropafenonePropranolol may increase the bradycardic activities of Propafenone.
ProtriptylineThe serum concentration of Propranolol can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Propranolol.
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Propranolol.
PTC299PTC299 may decrease the antihypertensive activities of Propranolol.
PyridostigminePyridostigmine may increase the bradycardic activities of Propranolol.
QuercetinThe serum concentration of Propranolol can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Propranolol is combined with Quetiapine.
QuinacrineThe serum concentration of Propranolol can be increased when it is combined with Quinacrine.
QuinaprilPropranolol may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Propranolol can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Propranolol.
QuinineThe serum concentration of Quinine can be increased when it is combined with Propranolol.
RamiprilRamipril may increase the hypotensive activities of Propranolol.
RanitidineThe serum concentration of Propranolol can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Propranolol.
RasagilineRasagiline may increase the hypotensive activities of Propranolol.
ReboxetineThe serum concentration of Propranolol can be increased when it is combined with Reboxetine.
RegorafenibRegorafenib may increase the bradycardic activities of Propranolol.
RemikirenRemikiren may increase the hypotensive activities of Propranolol.
RescinnaminePropranolol may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Propranolol.
ResveratrolResveratrol may decrease the antihypertensive activities of Propranolol.
RifabutinThe metabolism of Propranolol can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Propranolol can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Propranolol.
RifapentineThe metabolism of Propranolol can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Propranolol.
RilpivirineThe serum concentration of Propranolol can be increased when it is combined with Rilpivirine.
RiociguatPropranolol may increase the hypotensive activities of Riociguat.
RisperidonePropranolol may increase the hypotensive activities of Risperidone.
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Propranolol.
RitodrinePropranolol may decrease the bronchodilatory activities of Ritodrine.
RitonavirThe serum concentration of Propranolol can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Propranolol.
RituximabPropranolol may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Propranolol.
RivastigmineRivastigmine may increase the bradycardic activities of Propranolol.
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Propranolol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Propranolol.
RolapitantThe serum concentration of Propranolol can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Propranolol.
RopiniroleThe metabolism of Propranolol can be decreased when combined with Ropinirole.
RuxolitinibRuxolitinib may increase the bradycardic activities of Propranolol.
SafrazineSafrazine may increase the hypotensive activities of Propranolol.
SalbutamolPropranolol may decrease the bronchodilatory activities of Salbutamol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Propranolol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Propranolol.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Propranolol.
SalmeterolPropranolol may decrease the bronchodilatory activities of Salmeterol.
SalsalateSalsalate may decrease the antihypertensive activities of Propranolol.
SaprisartanPropranolol may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Propranolol can be decreased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Propranolol.
ScopolamineThe serum concentration of Propranolol can be increased when it is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Propranolol.
SelegilineSelegiline may increase the hypotensive activities of Propranolol.
SelexipagPropranolol may increase the hypotensive activities of Selexipag.
SeratrodastSeratrodast may decrease the antihypertensive activities of Propranolol.
SertralineThe serum concentration of Propranolol can be increased when it is combined with Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Propranolol.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Propranolol.
SiltuximabThe serum concentration of Propranolol can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Propranolol can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Propranolol can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Propranolol can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Propranolol.
SitaxentanPropranolol may increase the hypotensive activities of Sitaxentan.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Propranolol.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Propranolol.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Propranolol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Propranolol.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Propranolol.
SpiraprilPropranolol may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Propranolol.
SRT501SRT501 may decrease the antihypertensive activities of Propranolol.
St. John's WortThe serum concentration of Propranolol can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Propranolol can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Propranolol can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Propranolol can be decreased when it is combined with Streptozocin.
SufentanilPropranolol may increase the bradycardic activities of Sufentanil.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Propranolol.
SulfinpyrazoneThe serum concentration of Propranolol can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Propranolol can be decreased when combined with Sulfisoxazole.
SulindacSulindac may decrease the antihypertensive activities of Propranolol.
SumatriptanThe serum concentration of Propranolol can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Propranolol can be increased when it is combined with Sunitinib.
SuprofenSuprofen may decrease the antihypertensive activities of Propranolol.
TacrineTacrine may increase the bradycardic activities of Propranolol.
TacrolimusThe serum concentration of Propranolol can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Propranolol.
TadalafilTadalafil may increase the antihypertensive activities of Propranolol.
TamoxifenThe serum concentration of Propranolol can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Propranolol.
TamsulosinPropranolol may increase the orthostatic hypotensive activities of Tamsulosin.
Taurocholic AcidThe serum concentration of Propranolol can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Propranolol.
TelaprevirThe metabolism of Propranolol can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Propranolol.
TelithromycinThe metabolism of Propranolol can be decreased when combined with Telithromycin.
TelmisartanPropranolol may increase the hypotensive activities of Telmisartan.
TemocaprilPropranolol may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Propranolol.
TenofovirThe metabolism of Propranolol can be decreased when combined with Tenofovir.
TenoxicamTenoxicam may decrease the antihypertensive activities of Propranolol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Propranolol.
TerazosinThe risk or severity of adverse effects can be increased when Propranolol is combined with Terazosin.
TerbinafineThe metabolism of Propranolol can be decreased when combined with Terbinafine.
TerbutalinePropranolol may decrease the bronchodilatory activities of Terbutaline.
TerfenadineThe serum concentration of Propranolol can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Propranolol can be decreased when it is combined with Teriflunomide.
TerlipressinPropranolol may increase the hypotensive activities of Terlipressin.
TesmilifeneThe serum concentration of Propranolol can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Propranolol can be increased when it is combined with Testosterone.
TheophyllinePropranolol may decrease the bronchodilatory activities of Theophylline.
TheophyllineThe metabolism of Propranolol can be decreased when combined with Theophylline.
ThiamylalThiamylal may increase the hypotensive activities of Propranolol.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Propranolol.
ThiopentalThiopental may increase the hypotensive activities of Propranolol.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Propranolol.
ThioridazineThioridazine may increase the hypotensive activities of Propranolol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Propranolol.
TibolonePropranolol may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Propranolol.
TiclopidineThe metabolism of Propranolol can be decreased when combined with Ticlopidine.
TicrynafenPropranolol may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Propranolol.
TipranavirThe metabolism of Propranolol can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Propranolol is combined with Tizanidine.
TocilizumabThe serum concentration of Propranolol can be decreased when it is combined with Tocilizumab.
TofacitinibTofacitinib may increase the bradycardic activities of Propranolol.
TolazamidePropranolol may increase the hypoglycemic activities of Tolazamide.
TolazolinePropranolol may increase the hypotensive activities of Tolazoline.
TolbutamidePropranolol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Propranolol.
TolmetinTolmetin may decrease the antihypertensive activities of Propranolol.
ToloxatoneToloxatone may increase the hypotensive activities of Propranolol.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Propranolol.
TopiramateThe metabolism of Propranolol can be decreased when combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Propranolol.
TorasemideTorasemide may increase the hypotensive activities of Propranolol.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Propranolol.
TrandolaprilTrandolapril may increase the hypotensive activities of Propranolol.
TranilastTranilast may decrease the antihypertensive activities of Propranolol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Propranolol.
TranylcypromineTranylcypromine may increase the hypotensive activities of Propranolol.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Propranolol.
TravoprostTravoprost may increase the hypotensive activities of Propranolol.
TrazodoneThe serum concentration of Propranolol can be increased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Propranolol.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Propranolol.
TrichlorfonTrichlorfon may increase the bradycardic activities of Propranolol.
TrichlormethiazidePropranolol may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Propranolol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Propranolol.
TrimazosinPropranolol may increase the hypotensive activities of Trimazosin.
TrimethaphanPropranolol may increase the hypotensive activities of Trimethaphan.
TrimethoprimThe serum concentration of Propranolol can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Propranolol can be increased when it is combined with Trimipramine.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Propranolol.
TroleandomycinThe serum concentration of Propranolol can be increased when it is combined with Troleandomycin.
TubocurarineTubocurarine may increase the bradycardic activities of Propranolol.
UdenafilUdenafil may increase the antihypertensive activities of Propranolol.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Propranolol.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Propranolol.
UnoprostonePropranolol may increase the hypotensive activities of Unoprostone.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Propranolol.
ValsartanValsartan may increase the hypotensive activities of Propranolol.
VardenafilVardenafil may increase the antihypertensive activities of Propranolol.
VareniclineThe risk or severity of adverse effects can be increased when Propranolol is combined with Varenicline.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Propranolol.
VemurafenibThe serum concentration of Propranolol can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Propranolol can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Propranolol.
VerapamilThe risk or severity of adverse effects can be increased when Propranolol is combined with Verapamil.
VilanterolPropranolol may decrease the bronchodilatory activities of Vilanterol.
VilazodoneThe serum concentration of Propranolol can be increased when it is combined with Vilazodone.
VinblastineThe serum concentration of Propranolol can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Propranolol.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Propranolol.
VincristineThe serum concentration of Propranolol can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Propranolol can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Propranolol.
VoriconazoleThe metabolism of Propranolol can be decreased when combined with Voriconazole.
VortioxetineThe serum concentration of Propranolol can be increased when it is combined with Vortioxetine.
XylometazolinePropranolol may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Propranolol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Propranolol.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Propranolol.
ZileutonThe serum concentration of Propranolol can be increased when it is combined with Zileuton.
ZimelidineThe serum concentration of Propranolol can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Propranolol can be decreased when combined with Ziprasidone.
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Propranolol.
ZomepiracZomepirac may decrease the antihypertensive activities of Propranolol.
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Lewis CJ, Gong H, Brown MJ, Harding SE: Overexpression of beta 1-adrenoceptors in adult rat ventricular myocytes enhances CGP 12177A cardiostimulation: implications for 'putative' beta 4-adrenoceptor pharmacology. Br J Pharmacol. 2004 Mar;141(5):813-24. Epub 2004 Feb 2. [PubMed:14757703 ]
  3. Rouget C, Barthez O, Goirand F, Leroy MJ, Breuiller-Fouche M, Rakotoniaina Z, Guerard P, Morcillo EJ, Advenier C, Sagot P, Cabrol D, Dumas M, Bardou M: Stimulation of the ADRB3 adrenergic receptor induces relaxation of human placental arteries: influence of preeclampsia. Biol Reprod. 2006 Jan;74(1):209-16. Epub 2005 Sep 21. [PubMed:16177222 ]
  4. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611 ]
  5. Rezmann-Vitti LA, Louis SN, Nero TL, Jackman GP, Machida CA, Louis WJ: Site-directed mutagenesis of the rat beta1-adrenoceptor. Involvement of Tyr356 (7.43) in (+/-)cyanopindolol but not (+/-)[125Iodo]cyanopindolol binding. Eur J Med Chem. 2004 Jul;39(7):625-31. [PubMed:15236843 ]
  6. Yazawa K, Wang JW, Hao LY, Onoue Y, Kameyama M: Verrucotoxin, a stonefish venom, modulates calcium channel activity in guinea-pig ventricular myocytes. Br J Pharmacol. 2007 Aug;151(8):1198-203. Epub 2007 Jun 18. [PubMed:17572694 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Isaza C, Henao J, Ramirez E, Cuesta F, Cacabelos R: Polymorphic variants of the beta2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population. Methods Find Exp Clin Pharmacol. 2005 May;27(4):237-44. [PubMed:16082424 ]
  2. Rouget C, Barthez O, Goirand F, Leroy MJ, Breuiller-Fouche M, Rakotoniaina Z, Guerard P, Morcillo EJ, Advenier C, Sagot P, Cabrol D, Dumas M, Bardou M: Stimulation of the ADRB3 adrenergic receptor induces relaxation of human placental arteries: influence of preeclampsia. Biol Reprod. 2006 Jan;74(1):209-16. Epub 2005 Sep 21. [PubMed:16177222 ]
  3. Illingworth CJ, Gooding SR, Winn PJ, Jones GA, Ferenczy GG, Reynolds CA: Classical polarization in hybrid QM/MM methods. J Phys Chem A. 2006 May 25;110(20):6487-97. [PubMed:16706406 ]
  4. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name:
ADRB3
Uniprot ID:
P13945
Molecular Weight:
43518.615 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Berg T, Piercey BW, Jensen J: Role of beta1-3-adrenoceptors in blood pressure control at rest and during tyramine-induced norepinephrine release in spontaneously hypertensive rats. Hypertension. 2010 May;55(5):1224-30. doi: 10.1161/HYPERTENSIONAHA.109.149286. Epub 2010 Mar 15. [PubMed:20231523 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Smejkal-Jagar L, Boranic M: Serotonin and serotoninergic agents affect proliferation of normal and transformed lymphoid cells. Immunopharmacol Immunotoxicol. 1995 Feb;17(1):151-62. [PubMed:7759768 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Bailey SR, Elliott J: Evidence for different 5-HT1B/1D receptors mediating vasoconstriction of equine digital arteries and veins. Eur J Pharmacol. 1998 Aug 21;355(2-3):175-87. [PubMed:9760032 ]
  2. Choppin A, O'Connor SE: Presence of vasoconstrictor 5HT1-like receptors revealed by precontraction of rabbit isolated mesenteric artery. Br J Pharmacol. 1995 Jan;114(2):309-14. [PubMed:7881730 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T: Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol. 1995 Apr;39(4):421-31. [PubMed:7640150 ]
  2. Brosen K: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet. 1995;29 Suppl 1:20-5. [PubMed:8846619 ]
  3. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Carrillo JA, Benitez J: Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000 Aug;39(2):127-53. [PubMed:10976659 ]
  6. Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M, Narimatsu S: Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15. [PubMed:7895609 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T: Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol. 1995 Apr;39(4):421-31. [PubMed:7640150 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Lewis DF, Modi S, Dickins M: Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82. [PubMed:11996013 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Dudley AJ, Bleasby K, Brown CD: The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000 Sep;131(1):71-9. [PubMed:10960071 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  2. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D: The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release. 2004 Mar 24;95(3):447-53. [PubMed:15023456 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 28, 2016 02:27